Short answer · Medically reviewed summary · Last updated: 2026-05-08
Alopecia, particularly in its most common autoimmune form, alopecia areata, has been documented since antiquity, with the term first coined by Hippocrates in ancient Greece. While historical understanding evolved from theories of "humoral imbalance" to the modern recognition of T-cell-mediated autoimmune activity, medical science has progressed from primitive topical irritants to targeted biologic therapies. When was alopecia first described in medical literature? The history of alopecia dates back to the Hippocratic era, where the term was derived from the Greek word "alopex" (fox), referencing the patchiness of the hair loss often seen in the disease.
Alopecia, particularly in its most common autoimmune form, alopecia areata, has been documented since antiquity, with the term first coined by Hippocrates in ancient Greece. While historical understanding evolved from theories of "humoral imbalance" to the modern recognition of T-cell-mediated autoimmune activity, medical science has progressed from primitive topical irritants to targeted biologic therapies.
The history of alopecia dates back to the Hippocratic era, where the term was derived from the Greek word "alopex" (fox), referencing the patchiness of the hair loss often seen in the disease. For centuries, alopecia areata was poorly understood, frequently attributed to infectious agents or nervous system disorders. It was not until the late 19th century that medical professionals began to differentiate alopecia from other dermatological conditions, moving away from the folk belief that it was caused by "bad humors" or parasites.
The 20th century marked a paradigm shift in how we view alopecia. Researchers moved from descriptive observation to immunological investigation. Key milestones include:
Historical treatments for alopecia were often ineffective or even harmful, ranging from mercury ointments to blistering agents. Today, our approach is significantly more sophisticated. The FDA approval of JAK inhibitors represents a major breakthrough, moving beyond non-specific immunosuppressants to targeted pathway modulation. With 36 people with alopecia currently sharing their experiences on DiseaseMaps.org, the community plays a vital role in documenting the efficacy of these modern treatments in real-world settings.
Medical disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment.